These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26644009)

  • 1. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
    Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
    Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
    Kim BS; Lee JD; Kang WJ
    Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
    Bagheri B; Maurer AH; Cone L; Doss M; Adler L
    J Nucl Med; 2004 Aug; 45(8):1340-3. PubMed ID: 15299059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors.
    Nakajo M; Nakajo M; Fukukura Y; Jinguji M; Shindo T; Nakabeppu Y; Kamimura K; Yoneyama T; Takumi K; Yoshiura T
    Abdom Imaging; 2015 Aug; 40(6):1655-65. PubMed ID: 25382022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging.
    Gratz S; Kemke B; Kaiser W; Heinis J; Behr TM; Höffken H
    J Int Med Res; 2010; 38(2):633-44. PubMed ID: 20515577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients.
    He X; Caoili EM; Avram AM; Miller BS; Else T
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1448-1459. PubMed ID: 33524123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
    Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased (18)F-fluorodeoxyglucose accumulation in bilateral adrenal glands of the patients suffering from vasovagal reaction due to blood vessel puncture.
    Otomi Y; Shinya T; Otsuka H; Terazawa K; Irahara S; Nagase S; Takahashi A; Kubo M; Harada M
    Ann Nucl Med; 2016 Aug; 30(7):501-5. PubMed ID: 27256405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
    Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
    Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.